ANOROHCP.COM: Keyword Density Checker

Total words: 4647 | 2-word phrases: 1204 | 3-word phrases: 1374 | 4-word phrases: 1436

PAGE INFO

Title	Try to keep the title under 60 characters (40 characters) ANORO ELLIPTA Inhaler \| A COPD Treatment
Description	Try to keep the meta description between 50 - 160 characters (172 characters) Learn about ANORO ELLIPTA (umeclidinium & vilanterol inhalation powder), a LAMA/LABA combination therapy for patients with chronic obstructive pulmonary disease (COPD).
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

ONE WORD PHRASES 633 Words

#	Keyword	Frequency	Density
1	of	57	9.00%
2	with	47	7.42%
3	in	47	7.42%
4	anoro	41	6.48%
5	the	36	5.69%
6	and	33	5.21%
7	patients	33	5.21%
8	or	27	4.27%
9	for	26	4.11%
10	to	26	4.11%

TWO WORD PHRASES 1204 Words

#	Keyword	Frequency	Density
1	patients with	22	1.83%
2	of a	20	1.66%
3	in patients	16	1.33%
4	anoro is	12	1.00%
5	is not	9	0.75%
6	for the	9	0.75%
7	of the	8	0.66%
8	copd a	8	0.66%
9	et al	7	0.58%
10	treatment of	6	0.50%
11	with an	6	0.50%
12	adverse reactions	6	0.50%
13	with caution	6	0.50%
14	of anoro	6	0.50%
15	hypersensitivity to	6	0.50%
16	obstructive pulmonary	6	0.50%
17	1 1	6	0.50%
18	should be	5	0.42%
19	chronic obstructive	5	0.42%
20	caution in	5	0.42%

THREE WORD PHRASES 1374 Words

#	Keyword	Frequency	Density
1	in patients with	13	0.95%
2	anoro is not	7	0.51%
3	with caution in	5	0.36%
4	obstructive pulmonary disease	4	0.29%
5	the relief of	4	0.29%
6	asthma anoro is	4	0.29%
7	use with caution	4	0.29%
8	administration of anoro	4	0.29%
9	patients with copd	4	0.29%
10	patients with chronic	4	0.29%
11	for the relief	4	0.29%
12	relief of acute	4	0.29%
13	acute bronchospasm or	3	0.22%
14	bronchospasm or for	3	0.22%
15	the treatment of	3	0.22%
16	patients with asthma	3	0.22%
17	is not indicated	3	0.22%
18	not indicated for	3	0.22%
19	treatment of asthma	3	0.22%
20	copd anoro is	3	0.22%
21	of acute bronchospasm	3	0.22%
22	anoro is contraindicated	3	0.22%
23	is contraindicated in	3	0.22%
24	severe hypersensitivity to	3	0.22%
25	hypersensitivity to milk	3	0.22%
26	to milk proteins	3	0.22%
27	any of the	3	0.22%
28	or any of	3	0.22%
29	vilanterol or any	3	0.22%
30	umeclidinium vilanterol or	3	0.22%

FOUR WORD PHRASES 1436 Words

#	Keyword	Frequency	Density
1	in patients with copd	4	0.28%
2	for the relief of	4	0.28%
3	the relief of acute	4	0.28%
4	use with caution in	4	0.28%
5	anoro is not indicated	3	0.21%
6	proteins or who have	3	0.21%
7	milk proteins or who	3	0.21%
8	to milk proteins or	3	0.21%
9	or any of the	3	0.21%
10	severe hypersensitivity to milk	3	0.21%
11	coadministration of anoro with	3	0.21%
12	hypersensitivity to umeclidinium vilanterol	3	0.21%
13	to umeclidinium vilanterol or	3	0.21%
14	anoro is contraindicated in	3	0.21%
15	the treatment of asthma	3	0.21%
16	copd anoro is not	3	0.21%
17	hypersensitivity to milk proteins	3	0.21%
18	is not indicated for	3	0.21%
19	vilanterol or any of	3	0.21%
20	of acute bronchospasm or	3	0.21%
21	relief of acute bronchospasm	3	0.21%
22	al efficacy and safety	3	0.21%
23	et al efficacy and	3	0.21%
24	patients with chronic obstructive	3	0.21%
25	in patients with asthma	3	0.21%
26	with caution in patients	3	0.21%
27	umeclidinium vilanterol or any	3	0.21%
28	asthma anoro is not	2	0.14%
29	with asthma anoro is	2	0.14%
30	patients with asthma anoro	2	0.14%
31	efficacy and safety of	2	0.14%
32	ics in patients with	2	0.14%
33	corticosteroid ics in patients	2	0.14%
34	anoro without an inhaled	2	0.14%
35	with severe hypersensitivity to	2	0.14%
36	ingredients in anoro without	2	0.14%
37	obstructive pulmonary disease results	2	0.14%
38	patients with copd in	2	0.14%
39	trials with anoro a	2	0.14%
40	maintenance treatment of patients	2	0.14%

EXTERNAL LINKS

#	URL	Whois	Check
1	https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF	Whois	gskpro.com
2	https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF#page=29	Whois	gskpro.com
3	https://www.gskusmedicalaffairs.com	Whois	gskusmedicalaffairs.com
4	https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF	Whois	gskpro.com
5	https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF#page=29	Whois	gskpro.com
6	https://www.gskusmedicalaffairs.com/	Whois	gskusmedicalaffairs.com
7	https://www.anoro.com	Whois	anoro.com
8	https://gskpro.com/en-us/qpharma-saml-page3/	Whois	gskpro.com
9	https://www.anoro.com	Whois	anoro.com
10	https://gskpro.com/en-us/qpharma-saml-page3/	Whois	gskpro.com
11	https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF	Whois	gsksource.com
12	https://www.gskforyou.com	Whois	gskforyou.com
13	https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF	Whois	gskpro.com
14	https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF#page=29	Whois	gskpro.com
15	http://www.fda.gov/medwatch	Whois	fda.gov
16	https://us.gsk.com/en-us/legal-notices/	Whois	gsk.com
17	https://privacy.gsk.com/en-us/	Whois	gsk.com
18	https://us.gsk.com/en-us/about-our-ads/	Whois	gsk.com
19	https://www.contactus.gsk.com/hcp/	Whois	gsk.com
20	https://www.inva.com/	Whois	inva.com
21	https://us.gsk.com/	Whois	gsk.com

ANOROHCP.COM KEYWORD DENSITY CHECKER

PAGE INFO

ONE WORD PHRASES 633 Words

TWO WORD PHRASES 1204 Words

THREE WORD PHRASES 1374 Words

FOUR WORD PHRASES 1436 Words

EXTERNAL LINKS

Email Tools

Website Tools

ANOROHCP.COM KEYWORD DENSITY CHECKER

PAGE INFO

ONE WORD PHRASES 633 Words

TWO WORD PHRASES 1204 Words

THREE WORD PHRASES 1374 Words

FOUR WORD PHRASES 1436 Words

EXTERNAL LINKS

Email Tools

Website Tools

Modal Heading